Neutron capture therapy research in Australia.

Area of Science:

• Nuclear Medicine
• Radiation Oncology
• Biomedical Engineering

Background:

• Neutron capture therapy (NCT) research in Australia has expanded significantly since 1986.
• Broadened support includes universities, research institutes, and hospitals.

Purpose of the Study:

• To report progress in Australian NCT research, focusing on boron chemistry, in vitro experiments, and novel therapeutic approaches.
• To evaluate challenges and advancements in developing effective NCT strategies.

Main Methods:

• Development of an accurate boron assay technique.
• Synthesis of boron analogues (chlorpromazine, thiouracil) and decaborane conjugation with monoclonal antibodies.
• In vitro cell survival experiments using human melanoma and mouse cell lines with boronophenylalanine and boron tetraphenyl porphyrins in the Moata reactor.
• Electron microscopy for radiation-damaged morphology analysis.
• Evaluation of the B16 mouse melanoma line for in vivo studies.
• Beam calculations for the HIFAR reactor.
• Investigation of gadolinium-157 (157Gd) and the induced-Auger effect for NCT.

Main Results:

• Progress in boron chemistry, including assay techniques and compound synthesis.
• In vitro studies show differential radiation damage in cell lines.
• Challenges identified in developing therapeutic beams for the HIFAR reactor due to gamma dose.
• The B16 mouse line shows more efficacy than a non-existent melanotic melanoma line.
• The 157Gd-Auger effect demonstrates potential for causing DNA double-strand breaks.

Conclusions:

• Australian NCT research shows steady progress, particularly in boron compound development and in vitro validation.
• Challenges remain in optimizing therapeutic neutron beams and in vivo models.
• Emerging strategies utilizing 157Gd offer a promising new direction for NCT, targeting DNA integrity.